Engflag

Oricox

Quick links to important sections

Oricox

Oricox_FR

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option: Ankylosing Spondylitis, Arthritis,Osteoarthritis, Pain, Osteoarthritis, Gout, Gouty Arthritis, Rheumatoid Arthritis, Spondylitis, Dental, Surgery

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oricox

Property Description
Active Ingredient Etoricoxib
Form Film-coated tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Mechanism Selective Cyclooxygenase-2 (COX-2) inhibitor
Origin Synthetic compound

What Type of Medicine is Oricox?

Oricox is a medicinal product containing the active substance, Etoricoxib, which is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Etoricoxib is a synthetic compound specifically identified within the coxib subclass, denoting its mechanism as a highly selective Cyclooxygenase-2 (COX-2) inhibitor. This pharmacological distinction establishes the medication's core function: mitigating inflammation and pain by precisely targeting a key enzymatic pathway. The efficacy and safety profile of selective COX-2 inhibitors like Etoricoxib are widely recognized in pharmacological studies, supporting their use as effective non-opioid options.

Composition and Physical Form of Etoricoxib

The active ingredient is Etoricoxib, a sulfonamide derivative with a characteristic diphenylpyridine ring structure, confirmed as a single active ingredient product in this context. Oricox is consistently formulated as a film-coated tablet intended for oral administration. This specific solid dosage form is the standard presentation for Etoricoxib, facilitating systemic absorption. The compound itself is designated as a prescription-only medicine (Rx), which differentiates it from over-the-counter anti-inflammatory agents.

General Therapeutic Purpose and Action Profile

The overall therapeutic purpose of Oricox is to provide symptomatic relief by employing a targeted mechanism of action that reduces inflammation, pain (analgesic effect), and fever (antipyretic effect). Its function as a selective COX-2 inhibitor means the drug primarily acts by interrupting the synthesis of prostaglandins that are induced by inflammatory stimuli. This intervention is confirmed to offer reliable anti-inflammatory efficacy, for example, in scenarios involving acute pain or chronic musculoskeletal discomfort. This targeted action is clinically recognized for efficiently managing the body's inflammatory response while maintaining a clear action profile.

What side effects are possible with Oricox?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The safety profile of Oricox (Etoricoxib) is primarily focused on cardiovascular and gastrointestinal risks, consistent with the selective COX-2 inhibitor class.

Serious adverse reactions include cardiovascular thrombotic events (such as myocardial infarction and stroke), which are considered dose- and duration-dependent. Gastrointestinal complications like ulceration, bleeding, and perforation, though lower than some non-selective NSAIDs, remain a significant risk, particularly with concomitant use of low-dose aspirin or in elderly patients. Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome) have been reported rarely.

Safety Monitoring and Restrictions

Official regulatory documents emphasize the drug’s known renovascular safety profile (hypertension, edema, and congestive heart failure). Key safety measures include:

  • Blood Pressure Control: Blood pressure must be adequately controlled before starting treatment and should be monitored within two weeks after initiation and periodically thereafter.
  • Contraindications: Use is restricted in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, uncontrolled hypertension (persistently above 140/90 mmHg), and congestive heart failure (NYHA II–IV).

Elderly patients and those with compromised renal function require particular caution due to increased vulnerability to gastrointestinal and renal adverse effects.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Oricox

Overdose Scope

Documented overdose presentations:

  • Gastrointestinal distress, including nausea, vomiting, and epigastric pain.
  • Central Nervous System (CNS) effects, including lethargy and drowsiness.

Physiological systems affected (as stated in label):

  • Gastrointestinal (potential for bleeding).
  • Renal (potential for acute renal failure).
  • Cardiovascular (potential for hypertension).
  • Central Nervous System (potential for respiratory depression and coma).

Dose-related or exposure-related factors (if applicable):

  • Symptoms are documented following the over-ingestion of tablets.

Population-specific overdose notes (if applicable):

  • No distinct population-specific manifestations or management modifications for an overdose scenario are explicitly documented in the official regulatory documents.

Emergency-response statements (as written in official documents):

  • Management of overdose is primarily symptomatic and supportive.
  • Procedures to limit absorption, such as administering activated charcoal and/or an osmotic cathartic, are described.

When immediate medical help is required (label-derived phrasing only):

  • Medical attention must be sought immediately if more tablets than prescribed are taken.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents):

  • While initial presentations may be mild, overdose has the potential for serious or life-threatening outcomes, including gastrointestinal bleeding, acute renal failure, and coma.

Regulatory basis (EMA / FDA / etc.):

  • Information is consistent with the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) content and the U.S. Food and Drug Administration (FDA) documentation for the NSAID pharmacological class.

Overdose-context constraints (as defined in official documents):

  • No specific antidotes are known for Oricox overdose.

Resulting Overdose Structure

Official overdose statements:

  • Immediate medical attention is required upon taking too many tablets.
  • Overdose presentations include gastrointestinal distress, CNS effects, and the potential for severe outcomes like acute renal failure and hypertension.
  • Treatment is limited to symptomatic and supportive care, as no specific antidote is known.
  • Procedural steps, such as the use of activated charcoal and/or osmotic cathartic, are defined for management.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the Oricox overdose profile by listing specific symptoms and detailing the potential for serious, life-threatening organ system complications. The required emergency action is defined by a mandatory statement that immediate medical help must be sought in cases of over-ingestion, specifically because management relies on symptomatic and supportive care in the absence of a documented specific antidote.

Therapeutic Uses of Oricox

Quick Facts: Uses of Oricox

  • May help manage symptoms associated with: Osteoarthritis
  • May help manage symptoms associated with: Rheumatoid Arthritis
  • May help manage symptoms associated with: Ankylosing Spondylitis
  • May help manage symptoms associated with: Acute adult pain
  • May help provide relief for: Primary dysmenorrhea (menstrual pain)

Oricox is a therapeutic option indicated for the management of the signs and symptoms associated with several common inflammatory conditions. The medication may help relieve discomfort, stiffness, and swelling associated with osteoarthritis and rheumatoid arthritis in adults. It is also used to help manage the symptoms of juvenile rheumatoid arthritis in patients two years of age and older.

Additionally, Oricox is used to help manage the pain and inflammation associated with ankylosing spondylitis, a type of arthritis that primarily affects the spine.

The medication is also utilized for the management of acute adult pain and may provide relief for symptoms related to primary dysmenorrhea (menstrual pain). Its use is intended to support an improved quality of life and maintenance of function for patients experiencing these conditions. Decisions regarding treatment should be made in consultation with a qualified healthcare professional.

Eligibility and Restrictions for Use

The eligibility for Oricox (etoricoxib) is strictly defined by regulatory documents, focusing on patient history and physiological status.

Populations for Whom Use is Contraindicated

Use is prohibited in adults with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease (e.g., prior stroke or heart attack), and Congestive Heart Failure (NYHA II-IV). It is also contraindicated for individuals with uncontrolled hypertension (blood pressure persistently ge 140/90 mmHg), active gastrointestinal ulceration or bleeding, Inflammatory Bowel Disease, severe hepatic dysfunction (Child-Pugh ge 10), and severe renal impairment (creatinine clearance < 30 mL/min).

Age and Reproductive Status

Oricox is contraindicated in children and adolescents under 16 years of age. It is also prohibited during pregnancy and lactation (breastfeeding). Women attempting to conceive are not recommended to use the medicine.

Eligibility-Related Restrictions

Patients with cardiovascular risk factors (e.g., diabetes, smoking, hypertension) must be assessed carefully. Those with controlled hypertension require blood pressure monitoring within two weeks of starting treatment and regularly thereafter. For mild to moderate hepatic impairment (Child-Pugh 5–9), use is restricted and specific lower dose limits must not be exceeded.

What should I know about interactions with other medicines?

Oricox Interactions with other medicines and products

This section describes the officially documented interaction patterns of Oricox (Etoricoxib) as found in government regulatory documents.

Pharmacokinetic Interactions (Exposure Modification)

Co-administration with Rifampin, a potent inducer of hepatic metabolism, is documented to substantially decrease the plasma exposure of Etoricoxib. Conversely, Etoricoxib may increase the systemic exposure of several co-administered medicines. The steady-state Area Under the Curve (AUC) of Ethinyl Estradiol (a component of oral contraceptives) is increased by 50% to 60%. Etoricoxib may also cause an increase in the plasma levels of Lithium and the maximum plasma concentration (Cmax) of Digoxin. However, studies show that co-administration with Antacids or Ketoconazole does not result in clinically important pharmacokinetic changes.

Pharmacodynamic Interactions

Etoricoxib may interfere with the effects of other drug classes. When taken with Warfarin or other oral anticoagulants, there is a documented association with an approximate 13% increase in the International Normalized Ratio (INR), signifying an elevated risk of bleeding. The combination with low-dose Acetylsalicylic Acid (Aspirin) significantly increases the risk of gastrointestinal complications. Etoricoxib may also diminish the antihypertensive or natriuretic effect of Diuretics, ACE Inhibitors, and ARBs. Furthermore, the interaction with ACE Inhibitors or ARBs may result in a higher risk of renal function deterioration in specific populations, such as elderly or volume-depleted patients.

Mechanism of Action

Selective COX-2 Enzyme Inhibition

This mechanism centers on the drug's function as a selective inhibitor of the cyclooxygenase-2 ( COX-2) enzyme. . This targeted interaction modulates molecular signaling by blocking the active site necessary for COX-2 function.

Downstream Prostaglandin Synthesis Modulation

By blocking COX-2, Oricox reduces the local synthesis of prostaglandins, which are lipid-based chemical mediators in the body. Modifying these early molecular steps influences the concentration of these mediators at the cellular level and along the pathway.

Modulation of Peripheral Signaling Dynamics

The resulting lower concentration of specific mediators restricts changes in vascular tone and permeability and limits the sensitization of local sensory nerves. This cascade of events contributes to altered signaling dynamics within the peripheral tissue environment and produces predictable physiological adjustments.

Dosage and Administration Information

How to Use Oricox

The administration of Oricox (Etoricoxib) is based on the established route, dosing patterns, and duration limits for the medication. As a film-coated tablet, Oricox is intended exclusively for oral administration and may be taken with or without food.

Official Dosage and Schedule

The standard dosing schedule requires the medicine to be taken once daily (q.d.). The maximum recommended daily dose must not be exceeded. The exact dosage is dependent on the condition being managed, typically falling within a range of 30 mg to 120 mg.

Indication Type Daily Dosage Range Use Pattern
Chronic Management (e.g., Osteoarthritis) 30 mg, 60 mg, or 90 mg Long-term maintenance, subject to assessment.
Acute Management (e.g., Acute Pain) 120 mg Strictly limited to a short duration (e.g., maximum 8 days).

Procedural Guidelines and Constraints

The medication must be used at the lowest effective dose for the shortest possible duration necessary. If a dose is missed, it is advised not to take a double dose to compensate; the regular once-daily schedule should be resumed the following day at the usual time. Dose adjustments are mandatory for patients with certain degrees of hepatic impairment (liver dysfunction).

Recent Clinical Evidence

Research evidence / Overview of studies for Oricox

The clinical evaluation of Oricox has primarily involved Randomized Controlled Trials (RCTs). These trials compare the compound to either a placebo (an inactive substance) or to other common anti-inflammatory medications. The findings describe group patterns and help contextualize how patients reported their experience during the study period.

Evidence for Symptom Management in Osteoarthritis

Research examined the compound in adults with osteoarthritis (OA), a condition characterized by functional limitations and outcomes related to physical discomfort. The evaluation involved numerous large-scale, controlled trials, including those that monitored patient outcomes over extended periods, sometimes for up to a year. Studies monitored how patients reported changes in pain intensity and daily functioning or activity level, using specialized, validated questionnaires like the WOMAC scale.

Findings describe patterns observed in the studies where pain and function measurements evolved in the observed populations receiving the compound compared to those receiving a placebo or an active comparator. What remains uncertain is the long-term characterization of these outcomes. There is limited information for long-term outcomes on sustained findings related to pain outcomes for periods significantly exceeding one year.

Evidence for Symptom Management in Rheumatoid Arthritis and Ankylosing Spondylitis

Oricox was studied for its application in exploring how symptoms change over time in rheumatoid arthritis (RA) and ankylosing spondylitis (AS), conditions involving periods of heightened symptoms. Studies monitored the change in key inflammatory signs, such as tender and swollen joints, and used composite scores (like the ACR criteria) to measure overall descriptions of disease activity. For ankylosing spondylitis, studies explored outcomes related to functional imbalance, using scales such as the BASDAI and BASFI scores.

In both conditions, the research provided context on symptom evolution but does not determine whether an individual will respond similarly to the group patterns observed, nor does it address the compound's potential role in disease modification.

Key Studies & References MedlinePlus Drug Information - Etoricoxib

Frequently Asked Questions (FAQ)

Common questions about Oricox (FAQ)

Q: What is the difference between Oricox and other NSAIDs like Ibuprofen or Naproxen?

Oricox contains the active substance etoricoxib, which is classified as a selective cyclo-oxygenase-2 (COX-2) inhibitor. This means it works by specifically targeting one particular enzyme. In contrast, commonly known NSAIDs like Ibuprofen and Naproxen are generally described as non-selective.

Q: Does Oricox contain steroids or is it a type of steroid medicine?

Oricox is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its active substance, etoricoxib, is not a steroid medicine.

Q: How quickly does Oricox start to relieve pain after taking it?

Studies indicate that the effect may begin relatively quickly. The onset of the pain-relieving effect may be faster when the medication is taken without food.

Q: How long does the pain-relieving effect of one tablet of Oricox typically last?

In clinical trials examining acute pain, the effect of the recommended dose was observed to last for over 24 hours.

Q: Can Oricox be used for general back pain or muscle spasms?

Official information indicates the medication is specifically indicated for the symptomatic relief of chronic low back pain, in addition to other listed conditions like arthritis.

Q: Is Oricox known to cause stomach problems compared to other anti-inflammatory drugs?

The official safety profile notes a risk of gastrointestinal complications, including ulceration, bleeding, and perforation, which has occurred. This risk remains a significant consideration.

Q: What are the most common side effects people report when taking Oricox?

The most frequently reported side effect is abdominal pain. Other common effects include headache, dizziness, fluid retention (oedema), high blood pressure, palpitations, heartburn, and flu-like disease.

Q: Can Oricox cause dizziness or sleepiness, and should I avoid driving?

Dizziness and somnolence (drowsiness) are listed as reported side effects. Official information notes that if a person experiences these effects, or blurred vision, they may need to avoid driving or operating machines.

Q: Can Oricox be taken safely by people with diabetes?

Official warnings state that people with cardiovascular risk factors, such as diabetes, require careful assessment. The official label emphasizes that caution is needed in these populations.

Q: Can Oricox interact with over-the-counter cold and flu medications?

Regulatory documents note that co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), often found in cold and flu remedies, may lead to additive adverse effects. This is a documented interaction that requires attention.

Q: Is Oricox safe for older adults or those over 65 years of age?

Official information notes that no standard dosage adjustment is necessary for elderly patients. However, the label emphasizes that particular caution is required in this age group due to their increased vulnerability to adverse gastrointestinal and renal effects.

Q: Does Oricox affect blood clotting or platelet function?

Selective COX-2 inhibitors are noted in official documents as having no antiplatelet effect. For this reason, the medication is not intended to substitute for Aspirin in cardiovascular prevention.

Q: Can Oricox cause anxiety or affect mental alertness?

Official product information lists changes in mental state, such as anxiety and depression, as Uncommon adverse effects. Decreased mental acuity is also noted.

Q: Why does Oricox sometimes cause a dry mouth or change in taste?

Dry mouth and dysgeusia (a change in taste) are listed in official documents as Uncommon side effects associated with the medication.

Q: What are the signs of a serious allergic reaction to Oricox?

Signs of a hypersensitivity reaction that warrant immediate medical attention include the appearance of a skin rash or mucosal lesions, or swelling of the face, lips, tongue, or throat (known as angioedema).

Q: Does Oricox mask the symptoms of an infection or fever?

Since the medication works to reduce inflammation and fever (an antipyretic effect), it may mask fever and other signs that an infection is present.

Q: Is Oricox used in the treatment of post-dental surgery pain?

Yes, Oricox is indicated for the short-term treatment of moderate pain associated with dental surgery in adults and adolescents aged 16 and older.

Q: Can Oricox be taken on an empty stomach to make it work faster?

The medication may be taken with or without food. The onset of the effect may be faster when the dose is administered without food.

Q: Is it normal to feel flu-like symptoms after starting Oricox?

Yes, a flu-like disease (symptoms resembling the flu) is listed in official documentation as a Common side effect.

Q: What does research say about the long-term safety of Oricox?

Regulatory warnings state that the cardiovascular risks are considered to increase with both the dose and the duration of exposure. For this reason, the lowest effective daily dose for the shortest duration possible is emphasized in official guidance.

Q: Can Oricox interact with herbal supplements or vitamins?

Regulatory documents emphasize the importance of communicating all over-the-counter products, vitamins, and herbal supplements being used to a healthcare provider, due to the potential for interactions.

Q: What symptoms should prompt me to contact a doctor immediately while on Oricox?

Signs that may warrant immediate medical attention include evidence of serious allergic reactions (such as swelling or difficulty breathing) or signs of gastrointestinal bleeding, such as severe/persistent stomach pain or black stools.

Q: Is it possible for Oricox to affect my vision?

Blurred vision is listed in official product information as an Uncommon side effect.

Q: How does Oricox compare to Naproxen in terms of gastrointestinal risk?

The official safety profile notes a risk of gastrointestinal complications, such as ulcers and bleeding. This risk is still present and increases significantly when the medication is taken alongside low-dose Aspirin.

Q: Can Oricox be taken if I am allergic to Aspirin?

No, the medication is contraindicated (prohibited) for use in patients who have experienced allergic-type reactions—such as bronchospasm or hives—after taking Aspirin or other NSAIDs.

Q: Does Oricox cause weight changes or affect appetite?

Weight gain and a change in appetite (either an increase or a decrease) are listed as Uncommon side effects in official documents.

Q: What is the official guidance on consuming alcohol while taking Oricox?

Official guidance often notes the interaction with alcohol as unknown. The label emphasizes the importance of reviewing alcohol consumption with a healthcare provider.

How should Oricox be stored and disposed of?

How to Store and Dispose of Oricox

Official regulatory documents define specific conditions for storing and disposing of Oricox (Etoricoxib) to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30 C.
Protection Keep the tablets in a dry place and protected from light and moisture.
Packaging Store the medicine in its original package.
Stability Do not use the tablets after the expiry date printed on the carton.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Oricox must be handled as pharmaceutical waste. Disposal instructions require that the product be discarded according to local regulations or returned to a pharmacy. This process prevents release into the environment, which is required as the raw substance is classified as toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Oricox found in:

A-Z Index: